{"id":"https://openalex.org/W2597464530","doi":"https://doi.org/10.1097/md.0000000000006062","title":"The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy","display_name":"The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy","publication_year":2017,"publication_date":"2017-02-01","ids":{"openalex":"https://openalex.org/W2597464530","doi":"https://doi.org/10.1097/md.0000000000006062","mag":"2597464530","pmid":"https://pubmed.ncbi.nlm.nih.gov/28178157","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5313014"},"language":"en","primary_location":{"id":"doi:10.1097/md.0000000000006062","doi":"https://doi.org/10.1097/md.0000000000006062","is_oa":true,"landing_page_url":"https://doi.org/10.1097/md.0000000000006062","pdf_url":null,"source":{"id":"https://openalex.org/S28966261","display_name":"Medicine","issn_l":"0025-7974","issn":["0025-7974","1536-5964"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1097/md.0000000000006062","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003042121","display_name":"Nathana\u00eblle Montanier","orcid":"https://orcid.org/0000-0003-2748-5610","observed_orcids":["https://orcid.org/0000-0003-2748-5610"]},"institutions":[{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I198244214","display_name":"Universit\u00e9 Clermont Auvergne","ror":"https://ror.org/01a8ajp46","country_code":"FR","type":"education","lineage":["https://openalex.org/I198244214"]},{"id":"https://openalex.org/I4210087086","display_name":"European Neuroendocrine Tumor Society","ror":"https://ror.org/001qjw859","country_code":"DE","type":"other","lineage":["https://openalex.org/I4210087086"]},{"id":"https://openalex.org/I4210105654","display_name":"World Health Organization","ror":"https://ror.org/01f80g185","country_code":"CH","type":"government","lineage":["https://openalex.org/I4210105654"]},{"id":"https://openalex.org/I4210124119","display_name":"Centre Jean Perrin","ror":"https://ror.org/02pwnhd33","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124119"]},{"id":"https://openalex.org/I4210128870","display_name":"Centre Hospitalier Universitaire de Clermont-Ferrand","ror":"https://ror.org/02tcf7a68","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128870"]},{"id":"https://openalex.org/I4210163188","display_name":"Institut G\u00e9n\u00e9tique, Reproduction et D\u00e9veloppement","ror":"https://ror.org/052d1cv78","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210096427","https://openalex.org/I4210163188"]}],"countries":["CH","DE","FR"],"is_corresponding":true,"raw_author_name":"Nathana\u00eblle Montanier","raw_affiliation_strings":["CHU Clermont-Ferrand, Service d'endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques CHU Clermont-Ferrand, Service d'anatomopathologie CHU Clermont-Ferrand, Service de chirurgie et oncologie digestive Centre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand UMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere Centre de Lutte Contre le Cancer Jean Perrin, Service de M\u00e9decine nucl\u00e9aire, Clermont-Ferrand, France","Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU Clermont-Ferrand, Service d'endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques CHU Clermont-Ferrand, Service d'anatomopathologie CHU Clermont-Ferrand, Service de chirurgie et oncologie digestive Centre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand UMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere Centre de Lutte Contre le Cancer Jean Perrin, Service de M\u00e9decine nucl\u00e9aire, Clermont-Ferrand, France","institution_ids":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210124119","https://openalex.org/I4210128870","https://openalex.org/I4210163188"]},{"raw_affiliation_string":"Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210087086","https://openalex.org/I4210105654","https://openalex.org/I4210163188"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110290478","display_name":"Juliette Joubert\u2010Zakeyh","orcid":"https://orcid.org/0009-0008-6963-1392","observed_orcids":["https://orcid.org/0009-0008-6963-1392"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210087086","display_name":"European Neuroendocrine Tumor Society","ror":"https://ror.org/001qjw859","country_code":"DE","type":"other","lineage":["https://openalex.org/I4210087086"]},{"id":"https://openalex.org/I4210105654","display_name":"World Health Organization","ror":"https://ror.org/01f80g185","country_code":"CH","type":"government","lineage":["https://openalex.org/I4210105654"]},{"id":"https://openalex.org/I4210128870","display_name":"Centre Hospitalier Universitaire de Clermont-Ferrand","ror":"https://ror.org/02tcf7a68","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128870"]},{"id":"https://openalex.org/I4210163188","display_name":"Institut G\u00e9n\u00e9tique, Reproduction et D\u00e9veloppement","ror":"https://ror.org/052d1cv78","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210096427","https://openalex.org/I4210163188"]}],"countries":["CH","DE","FR"],"is_corresponding":false,"raw_author_name":"Juliette Joubert-Zakeyh","raw_affiliation_strings":["CHU Clermont-Ferrand, Service d\u2019anatomopathologie","Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU Clermont-Ferrand, Service d\u2019anatomopathologie","institution_ids":["https://openalex.org/I4210128870"]},{"raw_affiliation_string":"Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210087086","https://openalex.org/I4210105654","https://openalex.org/I4210163188"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016744212","display_name":"Caroline P\u00e9torin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210087086","display_name":"European Neuroendocrine Tumor Society","ror":"https://ror.org/001qjw859","country_code":"DE","type":"other","lineage":["https://openalex.org/I4210087086"]},{"id":"https://openalex.org/I4210105654","display_name":"World Health Organization","ror":"https://ror.org/01f80g185","country_code":"CH","type":"government","lineage":["https://openalex.org/I4210105654"]},{"id":"https://openalex.org/I4210128870","display_name":"Centre Hospitalier Universitaire de Clermont-Ferrand","ror":"https://ror.org/02tcf7a68","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128870"]},{"id":"https://openalex.org/I4210163188","display_name":"Institut G\u00e9n\u00e9tique, Reproduction et D\u00e9veloppement","ror":"https://ror.org/052d1cv78","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210096427","https://openalex.org/I4210163188"]}],"countries":["CH","DE","FR"],"is_corresponding":false,"raw_author_name":"Caroline P\u00e9torin","raw_affiliation_strings":["CHU Clermont-Ferrand, Service de chirurgie et oncologie digestive","Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU Clermont-Ferrand, Service de chirurgie et oncologie digestive","institution_ids":["https://openalex.org/I4210128870"]},{"raw_affiliation_string":"Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210087086","https://openalex.org/I4210105654","https://openalex.org/I4210163188"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108757358","display_name":"Pierre Fran\u00e7ois Montoriol","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210087086","display_name":"European Neuroendocrine Tumor Society","ror":"https://ror.org/001qjw859","country_code":"DE","type":"other","lineage":["https://openalex.org/I4210087086"]},{"id":"https://openalex.org/I4210105654","display_name":"World Health Organization","ror":"https://ror.org/01f80g185","country_code":"CH","type":"government","lineage":["https://openalex.org/I4210105654"]},{"id":"https://openalex.org/I4210124119","display_name":"Centre Jean Perrin","ror":"https://ror.org/02pwnhd33","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124119"]},{"id":"https://openalex.org/I4210163188","display_name":"Institut G\u00e9n\u00e9tique, Reproduction et D\u00e9veloppement","ror":"https://ror.org/052d1cv78","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210096427","https://openalex.org/I4210163188"]}],"countries":["CH","DE","FR"],"is_corresponding":false,"raw_author_name":"Pierre Fran\u00e7ois Montoriol","raw_affiliation_strings":["Centre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand","Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand","institution_ids":["https://openalex.org/I4210124119"]},{"raw_affiliation_string":"Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210087086","https://openalex.org/I4210105654","https://openalex.org/I4210163188"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060791155","display_name":"Salwan Maqdasy","orcid":"https://orcid.org/0000-0001-5164-9879","observed_orcids":["https://orcid.org/0000-0001-5164-9879"]},"institutions":[{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I198244214","display_name":"Universit\u00e9 Clermont Auvergne","ror":"https://ror.org/01a8ajp46","country_code":"FR","type":"education","lineage":["https://openalex.org/I198244214"]},{"id":"https://openalex.org/I4210087086","display_name":"European Neuroendocrine Tumor Society","ror":"https://ror.org/001qjw859","country_code":"DE","type":"other","lineage":["https://openalex.org/I4210087086"]},{"id":"https://openalex.org/I4210105654","display_name":"World Health Organization","ror":"https://ror.org/01f80g185","country_code":"CH","type":"government","lineage":["https://openalex.org/I4210105654"]},{"id":"https://openalex.org/I4210128870","display_name":"Centre Hospitalier Universitaire de Clermont-Ferrand","ror":"https://ror.org/02tcf7a68","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128870"]},{"id":"https://openalex.org/I4210163188","display_name":"Institut G\u00e9n\u00e9tique, Reproduction et D\u00e9veloppement","ror":"https://ror.org/052d1cv78","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210096427","https://openalex.org/I4210163188"]}],"countries":["CH","DE","FR"],"is_corresponding":false,"raw_author_name":"Salwan Maqdasy","raw_affiliation_strings":["CHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques","UMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere","Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques","institution_ids":["https://openalex.org/I4210128870"]},{"raw_affiliation_string":"UMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere","institution_ids":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210163188"]},{"raw_affiliation_string":"Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210087086","https://openalex.org/I4210105654","https://openalex.org/I4210163188"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033534729","display_name":"A. Kelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210087086","display_name":"European Neuroendocrine Tumor Society","ror":"https://ror.org/001qjw859","country_code":"DE","type":"other","lineage":["https://openalex.org/I4210087086"]},{"id":"https://openalex.org/I4210105654","display_name":"World Health Organization","ror":"https://ror.org/01f80g185","country_code":"CH","type":"government","lineage":["https://openalex.org/I4210105654"]},{"id":"https://openalex.org/I4210124119","display_name":"Centre Jean Perrin","ror":"https://ror.org/02pwnhd33","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124119"]},{"id":"https://openalex.org/I4210163188","display_name":"Institut G\u00e9n\u00e9tique, Reproduction et D\u00e9veloppement","ror":"https://ror.org/052d1cv78","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210096427","https://openalex.org/I4210163188"]}],"countries":["CH","DE","FR"],"is_corresponding":false,"raw_author_name":"Antony Kelly","raw_affiliation_strings":["Centre de Lutte Contre le Cancer Jean Perrin, Service de M\u00e9decine nucl\u00e9aire, Clermont-Ferrand, France","Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre de Lutte Contre le Cancer Jean Perrin, Service de M\u00e9decine nucl\u00e9aire, Clermont-Ferrand, France","institution_ids":["https://openalex.org/I4210124119"]},{"raw_affiliation_string":"Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.; Accepted January 13, 2017; Received July 29, 2016; Received in revised form November 28, 2016; The authors report no conflicts of interest.; This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0; aCHU Clermont-Ferrand, Service d\u2019endocrinologie, diab\u00e9tologie et maladies m\u00e9taboliques; cCHU Clermont-Ferrand, Service de chirurgie et oncologie digestive; dCentre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand; eUMR CNRS 6293, INSERM U1103, Universit\u00e9 Clermont-Auvergne, G\u00e9n\u00e9tique Reproduction et D\u00e9veloppement, Aubiere","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210087086","https://openalex.org/I4210105654","https://openalex.org/I4210163188"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5003042121"],"corresponding_institution_ids":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I198244214","https://openalex.org/I4210087086","https://openalex.org/I4210105654","https://openalex.org/I4210124119","https://openalex.org/I4210128870","https://openalex.org/I4210163188"],"apc_list":{"value":1950,"currency":"USD","value_usd":1950},"apc_paid":{"value":1950,"currency":"USD","value_usd":1950},"fwci":0.9163,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.75013619,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"96","issue":"6","first_page":"e6062","last_page":"e6062"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12505","display_name":"Peptidase Inhibition and Analysis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pancreatic-neuroendocrine-carcinoma","display_name":"pancreatic neuroendocrine carcinoma","score":0.9929999709129333},{"id":"https://openalex.org/keywords/peptide-receptor-radionuclide-therapy","display_name":"peptide receptor radionuclide therapy","score":0.9110000133514404},{"id":"https://openalex.org/keywords/somatostatin-receptor-2","display_name":"somatostatin receptor 2","score":0.9369999766349792},{"id":"https://openalex.org/keywords/ki-67-proliferation-index","display_name":"Ki-67 proliferation index","score":0.9039999842643738},{"id":"https://openalex.org/keywords/mitotic-index","display_name":"mitotic index","score":0.9909999966621399},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.9350000023841858},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7540000081062317},{"id":"https://openalex.org/keywords/tumor-heterogeneity","display_name":"tumor heterogeneity","score":0.8479999899864197}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9488135576248169},{"id":"https://openalex.org/C2993559085","wikidata":"https://www.wikidata.org/wiki/Q2126444","display_name":"Radionuclide therapy","level":2,"score":0.8051297664642334},{"id":"https://openalex.org/C3017732841","wikidata":"https://www.wikidata.org/wiki/Q25098597","display_name":"Peptide receptor","level":3,"score":0.7478246092796326},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5705715417861938},{"id":"https://openalex.org/C3020076753","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic carcinoma","level":4,"score":0.5364004373550415},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47321003675460815},{"id":"https://openalex.org/C3020482125","wikidata":"https://www.wikidata.org/wiki/Q1981276","display_name":"Neuroendocrine carcinoma","level":3,"score":0.4537199139595032},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4282481074333191},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.42297104001045227},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.40835535526275635},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.14250388741493225},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.11036679148674011}],"mesh":[{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009942","descriptor_name":"Organometallic Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017481","descriptor_name":"Receptors, Somatostatin","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D018278","descriptor_name":"Carcinoma, Neuroendocrine","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018278","descriptor_name":"Carcinoma, Neuroendocrine","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D060787","descriptor_name":"Neoplasm Grading","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1097/md.0000000000006062","doi":"https://doi.org/10.1097/md.0000000000006062","is_oa":true,"landing_page_url":"https://doi.org/10.1097/md.0000000000006062","pdf_url":null,"source":{"id":"https://openalex.org/S28966261","display_name":"Medicine","issn_l":"0025-7974","issn":["0025-7974","1536-5964"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4174763","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5313014","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5313014","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5313014","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine (Baltimore)","raw_type":"Text"},{"id":"pmid:28178157","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28178157","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine","raw_type":"Case Reports"}],"best_oa_location":{"id":"doi:10.1097/md.0000000000006062","doi":"https://doi.org/10.1097/md.0000000000006062","is_oa":true,"landing_page_url":"https://doi.org/10.1097/md.0000000000006062","pdf_url":null,"source":{"id":"https://openalex.org/S28966261","display_name":"Medicine","issn_l":"0025-7974","issn":["0025-7974","1536-5964"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1555094309","https://openalex.org/W1964586919","https://openalex.org/W1973230030","https://openalex.org/W1973577894","https://openalex.org/W1981002414","https://openalex.org/W2027676394","https://openalex.org/W2050083847","https://openalex.org/W2063178653","https://openalex.org/W2079241416","https://openalex.org/W2084288697","https://openalex.org/W2092706522","https://openalex.org/W2102617530","https://openalex.org/W2123060958","https://openalex.org/W2125398839","https://openalex.org/W2125719062","https://openalex.org/W2142658652","https://openalex.org/W2149995019","https://openalex.org/W2160463900","https://openalex.org/W2315116030","https://openalex.org/W2509018594"],"related_works":["https://openalex.org/W4327555631","https://openalex.org/W4402035801","https://openalex.org/W4400938881","https://openalex.org/W2995092729","https://openalex.org/W4302029349","https://openalex.org/W2883477055","https://openalex.org/W2911536495","https://openalex.org/W2905501684","https://openalex.org/W4402332442","https://openalex.org/W4313539346"],"abstract_inverted_index":{"RATIONALE:":[0],"Pancreatic":[1],"neuroendocrine":[2,40,59],"tumors":[3,9,41,140],"(pNET)":[4],"are":[5],"rare":[6],"slowly":[7],"growing":[8],"with":[10,20,87,93,115],"a":[11,27,80,83,116],"high":[12,118],"metastatic":[13,34,138],"potential.":[14],"Peptide":[15],"receptor":[16,44],"radionuclide":[17],"therapy":[18],"(PRRT)":[19],"radiolabeled":[21],"analogues":[22],"has":[23,66],"been":[24],"developed":[25],"as":[26],"new":[28],"tool":[29],"for":[30,102,176],"the":[31,48,51,68,106,125,130,147,150,177,181],"management":[32,52],"of":[33,53,70,82,132,152],"well-differentiated":[35],"(grade":[36],"1":[37],"and":[38,167],"2)":[39],"expressing":[42,141],"somatostatin":[43],"(SSTR2).":[45],"Chemotherapy":[46],"is":[47],"mainstay":[49],"in":[50,72,136],"grade":[54],"3":[55,103],"(G3)":[56],"unresectable":[57,137],"pancreatic":[58],"carcinoma":[60],"(pNEC).":[61],"To":[62],"date,":[63],"no":[64],"study":[65],"evaluated":[67],"efficacy":[69],"PRRT":[71,94,133,172],"such":[73],"tumors.":[74],"DIAGNOSES":[75],"AND":[76],"INTERVENTIONS:":[77],"We":[78],"describe":[79],"case":[81,145],"progressive":[84],"G3":[85,139,153],"pNEC":[86],"huge":[88],"liver":[89],"metastases":[90],"successfully":[91],"treated":[92],"(Lu":[95],"DOTATATE).":[96],"OUTCOMES:":[97],"Complete":[98],"remission":[99],"was":[100,109],"obtained":[101],"years.":[104],"Indeed,":[105],"mitotic":[107],"index":[108,120],"low":[110],"(as":[111],"G2":[112],"tumors)":[113],"but":[114],"very":[117],"Ki-67":[119],"(45%-70%).":[121],"Such":[122],"discordance":[123],"between":[124],"proliferative":[126],"markers":[127],"should":[128,157],"consider":[129],"use":[131],"before":[134,180],"chemotherapy":[135],"SSTR2.":[142],"LESSONS:":[143],"This":[144],"supports":[146],"hypotheses":[148],"highlighting":[149],"heterogeneity":[151],"pNEC.":[154],"The":[155],"latter":[156],"be":[158,174],"subdivided":[159],"into":[160],"2":[161],"distinct":[162],"categories:":[163],"proliferation-discordant":[164],"(well":[165],"differentiated)":[166,170],"concordant":[168],"(poorly":[169],"NEC.":[171],"could":[173],"suggested":[175],"former":[178],"group":[179],"conventional":[182],"chemotherapy.":[183]},"counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2017-04-07T00:00:00"}